We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Akebia Therapeutics Inc (AKBA) USD0.00001

Sell:$1.97 Buy:$2.00 Change: $0.04 (1.96%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $0.04 (1.96%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $0.04 (1.96%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in dialysis-dependent (DD)-CKD adult patients and the treatment of iron deficiency anemia (IDA), in non-dialysis dependent (NDD)-CKD adult patients. Ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

Contact details

245 1st St
United States
+1 (617) 8712098

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$364.78 million
Shares in issue:
174.55 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • John Butler
    President, Chief Executive Officer, Director
  • David Spellman
    Chief Financial Officer, Senior Vice President, Treasurer
  • Michel Dahan
    Chief Operating Officer, Senior Vice President
  • Nicole Hadas
    Senior Vice President, Chief Legal Officer, Corporate Secretary
  • Steven Burke
    Senior Vice President, Research and Development and Chief Medical Officer
  • Dell Faulkingham
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.